ESR1 and breast cancer: These results suggest that PTK6 may be involved in regulating the growth and survival of drug-resistant ER + breast cancer cells and with drug resistance to endocrine therapy, thereby supporting combined ER/PTK6 targeting of ER + breast cancer [48, 49].